IRBIT Interacts with the Catalytic Core of Phosphatidylinositol Phosphate Kinase Type Iα and IIα through Conserved Catalytic Aspartate Residues

Hideaki Ando1*, Matsumi Hirose1, Laura Gainche1, Katsuhiro Kawaai1, Benjamin Bonneau1, Takeshi Ijuin2, Toshiki Itoh3, Tadaomi Takenawa3, Katsuhiko Mikoshiba1*

1 Laboratory for Developmental Neurobiology, RIKEN Brain Science Institute, Wako, Saitama, Japan, 2 Division of Biochemistry, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan, 3 Biosignal Research Center, Organization of Advanced Science and Technology, Kobe University, Kobe, Hyogo, Japan

* andohide@brain.riken.jp (HA); mikosiba@brain.riken.jp (KM)

Abstract

Phosphatidylinositol phosphate kinases (PIPKs) are lipid kinases that generate phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), a critical lipid signaling molecule that regulates diverse cellular functions, including the activities of membrane channels and transporters. IRBIT (IP3R-binding protein released with inositol 1,4,5-trisphosphate) is a multifunctional protein that regulates diverse target proteins. Here, we report that IRBIT forms signaling complexes with members of the PIPK family. IRBIT bound to all PIPK isoforms in heterologous expression systems and specifically interacted with PIPK type Iα (PIPKIα) and type IIα (PIPKIIα) in mouse cerebellum. Site-directed mutagenesis revealed that two conserved catalytic aspartate residues of PIPKIα and PIPKIIα are involved in the interaction with IRBIT. Furthermore, phosphatidylinositol 4-phosphate, Mg2+, and/or ATP interfered with the interaction, suggesting that IRBIT interacts with catalytic cores of PIPKs. Mutations of phosphorylation sites in the serine-rich region of IRBIT affected the selectivity of its interaction with PIPKIα and PIPKIIα. The structural flexibility of the serine-rich region, located in the intrinsically disordered protein region, is assumed to underlie the mechanism of this interaction. Furthermore, in vitro binding experiments and immunocytochemistry suggest that IRBIT and PIPKIIα interact with the Na+/HCO3− cotransporter NBCe1-B. These results suggest that IRBIT forms signaling complexes with PIPKIIα and NBCe1-B, whose activity is regulated by PI(4,5)P2.

Introduction

The hydrolysis of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) in response to the activation of cell surface receptors generates inositol 1,4,5-trisphosphate (IP3), which then activates IP3 receptors (IP3Rs) that are intracellular Ca2+ channels located mainly on the endoplasmic reticulum [1]. We previously identified an IP3R-binding protein termed IRBIT (IP3R-binding...
protein released with inositol 1,4,5-trisphosphate) from rat cerebellum [2]. IRBIT binds to the IP₃-binding domain of IP₃R through amino acids that interact with IP₃, and prevents the activation of IP₃R by competitively blocking access of IP₃ to IP₃R [3–5]. IRBIT comprises an N-terminal domain containing a serine-rich region and a C-terminal domain homologous to methylation pathway enzyme S-adenosylhomocysteine hydrolase (AHCY) [2, 6]. The serine-rich region of IRBIT contains multiple phosphorylation sites [3, 6–8]. Priming phosphorylation at Ser68 induces sequential phosphorylation at Ser71, Ser74, and Ser77 by casein kinase I, which requires a priming phosphate located three amino acids upstream of the target serine/threonine [3, 7]. The phosphorylations of these serine residues are critical for the interaction with IP₃R [3, 7]. Thr82, Ser84, and Ser85 are phosphorylated in mouse brain [8], however, their functional significance remain unknown.

IRBIT is a multifunctional protein that regulates several target proteins [6], including the Na⁺/HCO₃⁻ cotransporters NBCe1-B [9–14] and NBCn1-A [13], the Na⁺/H⁺ exchanger NHE3 [15–17], cystic fibrosis transmembrane conductance regulator [10, 18, 19], the Cl⁻/HCO₃⁻ exchanger Slc26a6 [19], Fip1 [20], ribonucleotide reductase [21], and calcium/calmodulin-dependent protein kinase IIa [22]. In most cases, interactions between IRBIT and these proteins depend on positively charged amino acids in the target proteins [3, 6, 13]; however, the molecular mechanisms by which IRBIT interacts with such diverse proteins remain largely unknown. IRBIT knockout mice show defects in secretion from pancreatic ducts [19] and behavioral abnormalities [22], suggesting multiple IRBIT functions in vivo.

Phosphatidylinositol phosphate kinases (PIPKs) are lipid kinases responsible for the production of PI(4,5)P₂, an important lipid signaling molecule that regulates numerous cellular processes, including cytoskeletal assembly, endocytosis/exocytosis, vesicular trafficking, cell migration, and ion channel and transporter functions [23–26]. The PIPK family is divided into two main subfamilies with distinct substrate specificities. Type I PIPKs, including PIPKIα [27, 28], PIPKIβ [27, 28], and PIPKIγ [29], phosphorylate phosphatidylinositol 4-phosphate (PI4P) at the 5 position of the inositol ring, whereas type II PIPKs, including PIPKIα [30], PIPKIβ [31], and PIPKIγ [32], phosphorylate phosphatidylinositol 5-phosphate (PI5P) at the 4 position of the inositol ring [33]. PIPKs share a common structure, with a conserved kinase domain and divergent N- and C-termini [25, 26]. Intracellular localization of PIPKs is regulated in part by protein-protein interactions that include associations with PI(4,5)P₂ effectors. Thus, the synthesis of PI(4,5)P₂ is coupled to its utilization [24, 34].

To gain further insight into the function of IRBIT, we previously performed proteomic analysis of IRBIT-interacting proteins [20]. One of these proteins belongs to the PIPK family. As described above, PI(4,5)P₂ produced by PIPKs functions as a precursor of IP₃, an agonist of IP₃R. In addition, PI(4,5)P₂ regulates the activity of NBCe1-B [13, 35]. These relationships between PI(4,5)P₂ and IRBIT-binding proteins suggest that IRBIT is involved in forming signaling complexes containing PIPKs and PI(4,5)P₂ effectors. In this study, we analyzed the interactions of IRBIT with the PIPK family. We determined the isoform specificity of the interaction between IRBIT and PIPK family members. We elucidated the intriguing molecular mechanisms by which the phosphorylation sites of IRBIT bind to the catalytic core of PIPKs. Furthermore, we described potential signaling complexes containing IRBIT, PIPKs, and NBCe1-B.

**Materials and Methods**

**Plasmids**

Hemagglutinin (HA)-tagged IRBIT and its site-directed mutants were described previously [3]. Deletion mutants of IRBIT were generated by subcloning truncated cDNA fragments of IRBIT into pHM6 (Boehringer Mannheim). pcDNA3-IRBIT was generated by subcloning the cDNA
encoding mouse IRBIT into pcDNA3 (Invitrogen). Mouse PIPKIα, PIPKIβ, and PIPKIγ, and rat PIPKIIα, PIPKIIβ, and PIPKIIγ were cloned into pEF-Bos-myc mammalian expression vectors as described previously [36]. The nomenclature of PIPKIα and PIPKIβ are different in mouse and human [27, 28] and we use the human nomenclature in this study according to the revised nomenclature in the current GenBank database. Site-directed mutants of PIPKIα and PIPKIIα were generated using QuickChange II Site-Directed Mutagenesis Kit (Stratagene). Deletion mutants of PIPKIα and PIPKIIα were generated by subcloning truncated cDNA fragments of PIPKIα and PIPKIIα into pEF-Bos-myc. Bacterial expression vector encoding PIPKIα and PIPKIIα fused to glutathione S-transferase (GST) was generated by subcloning cDNA encoding PIPKIα and PIPKIIα into pGEX-4T-1 (GE healthcare). Green fluorescent protein (GFP)-tagged NBCe1-B was described previously [9].

Antibodies
Rabbit anti-IRBIT antibody was described previously [2]. Mouse anti-myc (9E10), goat anti-PIPKIα (C-17), anti-PIPKIβ (D-19), anti-PIPKIγ (M-19), anti-PIPKIIα (N-19), anti-PIPKIIβ (A-15), and control goat IgG were obtained from Santa Cruz Biotechnology. Rat anti-HA (3F10) and mouse anti-myc antibody conjugated with peroxidase were obtained from Roche Applied Science. Donkey anti-rabbit IgG conjugated with horseradish peroxidase (HRP) and goat anti-rat IgG conjugated with HRP were obtained from GE healthcare. Rabbit anti-goat IgG conjugated with HRP was obtained from Medical & Biological Laboratories. Rabbit anti-HA, Alexa Fluor 594-conjugated goat anti-rabbit IgG, and Alexa Fluor 488 or Alexa Fluor 647-conjugated goat anti-mouse IgG were obtained from Invitrogen.

Cell culture and transfection
Mouse embryonic fibroblast (MEF) cells derived from IRBIT knockout mice were described previously [22]. MEF cells, COS-7 cells, and HeLa cells were maintained in Dulbecco’s modified Eagle’s medium (Nacalai Tesque) supplemented with 10% fetal bovine serum (Equitech-Bio), 50 units/ml penicillin, and 50 μg/ml streptomycin (Nacalai Tesque) in a 5% CO2 incubator at 37°C. Transfection was performed at 20%–30% confluency using TransIT transfection reagents (Mirus) according to manufactures’ instruction.

Immunoprecipitation
Fifteen to eighteen hours after transfection, COS-7 cells were lysed in lysis buffer (10 mM Hepes [pH 7.4], 100 mM NaCl, 2 mM EDTA, and 1% Nonidet P-40) for 30 min at 4°C, followed by centrifugation (20,000 x g, 30 min). The supernatants were incubated with protein G-Sepharose beads (GE healthcare) for 1 hr at 4°C to clarify nonspecific binding to the beads. The clarified supernatants were incubated with 0.5 μg anti-myc or 0.2 μg anti-HA antibody for 1 hr at 4°C, and immune complex was isolated by the addition of 5 μl protein G-Sepharose beads for 1 hr at 4°C. The complex was spun down and washed three times with lysis buffer. Precipitated proteins were eluted by boiling in SDS-PAGE sample buffer and analyzed by immunoblotting with appropriate antibodies.

For immunoprecipitation from cerebellum, adult mouse cerebella were homogenized in 9 volumes of 10 mM Hepes buffer (pH 7.4) containing 320 mM sucrose, 2 mM EDTA, 1 mM 2-mercaptoethanol, and protease inhibitor cocktail (Roche Applied Science) with a glass-Teflon homogenizer (950 rpm, 10 strokes). The homogenate was centrifuged at 1,000 x g for 10 min, and the supernatant was centrifuged at 100,000 x g for 30 min to obtain cytosolic fraction (the supernatant) and membrane fraction (the pellet). The membrane fraction was solubilized in 50 mM Hepes, 2 mM EDTA, 1% Nonidet P-40, and protease inhibitors for 30 min at 4°C,
followed by centrifugation (20,000 x g, 30 min). The supernatant was added with 100 mM NaCl and diluted two times with immunoprecipitation buffer (10 mM Hepes [pH 7.4], 100 mM NaCl, 2 mM EDTA, and 0.5% Nonidet P-40). The cytosolic and the solubilized membrane fractions were pre-cleared with protein G-Sepharose beads for 1 hr at 4°C, and the clarified supernatants were incubated with 2 μg anti-PIPK or control antibody pre-bound to 5 μl protein G-Sepharose beads for 2 hr at 4°C. The complex was spun down and washed three times with immunoprecipitation buffer. All animal studies were carried out in accordance with the guidelines and approval from the Animal Experiments Committee at the RIKEN Wako Institute (Approval number: H27-2-202).

**Pull-down assay**

GST-tagged PIPKIα, PIPKIIα, and site-directed mutants of PIPKIα were expressed in E. coli (JM109 strain) using 100 μM isopropyl-β-D-thio-galactoside (IPTG) for 4 hr at 25°C, and purified with glutathione-Sepharose 4B (GE healthcare). The recombinant IRBIT protein expressed in Sf9 cells [3], the IP3 binding domain of IP3R1 (residues 224–604) fused to GST (GST-IP3BD) [2], and the N-terminal cytoplasmic domain of NBCe1-B (residues 1–468) fused to maltose-binding protein (MBP-NBCe1-B/N) [9] were described previously. For GST pull-down assay, cell lysates prepared as described above were incubated with 10 μg GST fusion proteins for 1 hr at 4°C. After the addition of 10 μl glutathione-Sepharose 4B, the samples were incubated for 1 hr at 4°C. The resins were washed three times with lysis buffer, and bound proteins were eluted with 20 mM glutathione. Pull-down assay using recombinant IRBIT protein (1 μg) were performed in pull-down buffer (10 mM Hepes [pH 7.4], 100 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 1 mM 2-mercaptoethanol, and 0.01% Nonidet P-40) containing the indicated concentrations of PI4P, PI5P (CellSignals), IP3 (Dojindo), adenosine 5’-triphosphate (ATP), adenosine 5’-diphosphate (ADP), or thymidine 5’-triphosphate (TTP) (Sigma). The resins were washed three times with pull-down buffer. For MBP pull-down assay, cell lysates were incubated with 5 μg MBP fusion proteins for 1 hr at 4°C. After the incubation with 10 μl amylase resin (New England Biolabs) for 1 hr at 4°C, the resins were washed three times with lysis buffer, and bound proteins were eluted with 100 mM maltose. Eluted proteins were analyzed by immunoblotting with appropriate antibodies or Coomassie brilliant blue (CBB) staining.

**Immunoblotting**

Samples were separated by SDS-PAGE and transferred onto polyvinylidene fluoride membrane (Millipore) by electroblotting. After blocking with 5% skim milk in PBS containing 0.1% Tween 20 (PBS-T) for 1 h at room temperature, membranes were immunoblotted with primary antibodies diluted in PBS-T containing 3% skim milk at the appropriate concentrations (anti-HA, 0.1 μg/ml; anti-myc conjugated with peroxidase, 0.5 μg/ml; other antibodies, 1 μg/ml) for 1 h at room temperature. After washing three times with PBS-T, the membrane was incubated with appropriate secondary antibodies conjugated with HRP diluted in PBS-T for 1 h at room temperature. When signals derive from goat antibodies used in the immunoprecipitation overlap those of immunoprecipitated proteins, the secondary antibody of the Immunocruz™ IP/WB Optima D system (Santa Cruz Biotechnology) was used. After washing three times with PBS-T, immunoreactive bands were visualized with the ECL detection system (GE healthcare), and were captured using a luminescent image analyzer (LAS-4000 mini, GE healthcare). Band intensities were quantified using ImageJ software.
Prediction of intrinsic disorder

Disordered/unstructured regions of IRBIT were analyzed by meta-prediction programs, MetaDisorder (http://genesilico.pl/metadisorder/, version MD2) [37], PONDR-FIT (http://www.disprot.org/pondr-fit.php) [38], and metaPrDOS (http://prdos.hgc.jp/cgi-bin/meta/top.cgi) [39].

Measurement of PIPK activity

In vitro lipid kinase assays were performed as described previously [32, 36] with modifications. Lysates of transfected COS-7 cells or MEF cells were incubated with 2 μg appropriate antibodies for 2 hr at 4°C. The immune complex was isolated by the addition of 10 μl protein G-Sepharose beads for 1hr at 4°C. The complex was spun down and washed three times with lysis buffer and three times with reaction buffer (50 mM Tris-HCl [pH 7.5], 100 mM NaCl, 1mM MgCl₂, and 1mM EGTA). For PIPKIα activity, the reaction was started by adding 50 μM PI4P, 50 μM ATP, and 10 μCi of [γ-32P]ATP (PerkinElmer Life Sciences) in 50 μl. For PIPKIIα activity, 50 μM PI5P was used instead of PI4P. After incubation for 10–20 min at 37°C, the lipids were extracted with chloroform/methanol and spotted onto TLC plates (Merck). The plates were developed in chloroform/methanol/ammonia/water, and the products were observed by autoradiography. PI(4,5)P₂ production was quantified by a liquid scintillation counter (Packard/PerkinElmer).

Immunocytochemistry

Transfected HeLa cells grown on glass coverslips were washed once with PBS, fixed in 4% formaldehyde in PBS for 15 min, permeabilized in 0.1% Triton X-100 in PBS for 5 min, and blocked in PBS containing 2% normal goat serum (Vector Laboratories) for 60 min at room temperature. Cells were then stained with rabbit anti-HA (1 μg/ml) and mouse anti-myc (1 μg/ml) for 60 min at room temperature. Following four 5-min PBS washes, Alexa Fluor 594-conjugated goat anti-rabbit IgG (1 μg/ml) and Alexa Fluor 488 or 647-conjugated goat anti-mouse IgG (1 μg/ml) were applied for 45 min at room temperature. Following four 5-min PBS washes, the coverslips were mounted with Vectashield (Vector Laboratories) and observed under a confocal fluorescence microscopy (FV1000, Olympus) with a ×60 objective. Fluorescence images were analyzed by FV10-ASW software (Olympus). The average fluorescence intensity of the two cell edges were defined as the plasma membrane and regions between the cell edges were defined as cytosol.

Results and Discussion

IRBIT interacts with PIPKIα and PIPKIIα in cerebellum

We previously reported proteomic analysis of IRBIT-interacting proteins, where IRBIT was overexpressed in 293EBNA cells and proteins immunoprecipitated with IRBIT were analyzed by mass spectrometry [20]. Among the proteins identified was a protein belonging to the PIPK family, PIPK IIγ [32]. Here we investigated the interaction of IRBIT with the PIPK isoforms PIPK Iα, PIPK Iβ, PIPK Iγ, PIPK IIα, PIPK IIβ, and PIPK IIγ (human nomenclature is used in this study). IRBIT and each isoform of the PIPK family were transfected into COS-7 cells, and co-immunoprecipitation assays were performed. IRBIT interacted with all PIPK isoforms in the heterologous expression system (Fig 1A, S1 Fig).

Further, we tested the interaction of IRBIT with PIPK family members in vivo. Mouse cerebella, where IRBIT is highly expressed [2, 40], were fractionated into cytosolic and membrane fractions and processed for immunoprecipitation using antibodies specific to each PIPK
isoform. IRBIT was clearly detected in the anti-PIPKIα immunoprecipitates from the cytosol fraction and in the anti-PIPKIα and anti-PIPKIIα immunoprecipitates from the membrane fraction (Fig 1B, S1 Fig). Faint evidence of IRBIT was observed in the anti-PIPKIγ immunoprecipitates from the membrane fraction (Fig 1B, S1 Fig). These results indicate that isoform specificity exists in vivo, and IRBIT mainly binds to PIPKIα and PIPKIIα in mouse cerebellum. The restriction of IRBIT/PIPKIIα interaction to the membrane fraction might be accounted for by the observation that IRBIT is more highly phosphorylated in membrane than in cytosolic fractions [40]. Although these results do not exclude the possibility that IRBIT interacts with other PIPK isoforms in different tissues, we hereafter focused on its interaction with PIPKIα and PIPKIIα.

Conserved catalytic amino acids of PIPKIα and PIPKIIα are required for interaction with IRBIT

PIPK family members have a conserved kinase homology domain and divergent N- and C-terminal regions [25, 27] (Fig 2A). To identify the regions responsible for binding to IRBIT, we analyzed the interaction of IRBIT with deletion mutants of PIPKIα and PIPKIIα. The C-terminal deletion mutants PIPKIα-(1–507) and PIPKIα-(1–438) bound to IRBIT, whereas PIPKIα-(1–430) showed significantly decreased affinity to IRBIT (Fig 2A and 2B). The expression levels of the N-terminal truncation mutants, PIPKIα-(57–546) and PIPKIα-(97–546), were much lower than that of wild-type PIPKIα (Fig 2A and 2B). These results suggest that amino acids 431–438 of PIPKIα are critical for the interaction with IRBIT, and the N-terminal divergent regions are essential for the stability of PIPKIα. Deletion of the N-terminal region of PIPKIIα resulted in low expression and reduced interaction with IRBIT (Fig 2A and 2C).

Although the homology of primary sequences of the kinase domains of type I and type II PIPKs is not very high (30%–40% identity) [27–32], their 3D structures are assumed to be well conserved [41, 42]. Considering that all PIPK isoforms bind to IRBIT in a heterologous expression system (Fig 1A, S1 Fig), the conserved kinase homology domain is expected to be involved in the interaction with IRBIT. Our previous study showed that IRBIT binds to the IP3-binding core of IP3R via amino acids essential for IP3 recognition [2, 3]. Similarity in chemical structures between IP3 and the PIPK substrates, PI4P and PI5P, both having an inositol ring and two or three phosphoryl groups, prompted us to investigate whether IRBIT interacts with the catalytic core of PIPKIα and PIPKIIα. Structural homologies between PIPK family members and protein kinases and mutagenesis analysis showed that Lys179, Asp307, and Asp389 of PIPKIα, and the corresponding Lys145, Asp273, and Asp359 of PIPKIIα are located in the catalytic core and are essential for enzymatic activity [29, 41–43] (Fig 2A). These residues are completely conserved among PIPK family members (Fig 2D). We introduced mutations in Lys179, Asp307, and Asp389 of PIPKIα and tested their interaction with IRBIT. Co-immunoprecipitation assays revealed that the D389A mutant displayed slightly decreased affinity for IRBIT, and that the double mutation D307A/D389A further decreased the interaction with IRBIT (Fig 2E). To exclude the indirect effect of actin re-organization induced by PIPKIα overexpression [44] on this interaction, we performed pull-down assays using recombinant GST fusion proteins of PIPKIα mutants. We found that the D307A and D389A mutants exhibited reduced binding to IRBIT, and the double mutant D307A/D389A displayed further diminished interactions (Fig 2F). Similar results were obtained for PIPKIIα. Mutation of Asp273 or Asp359 of PIPKIIα, corresponding to Asp307 and Asp389 of PIPKIα, respectively, slightly decreased PIPKIIα binding to IRBIT, and the double mutation D273A/D359A markedly weakened this interaction (Fig 2G). Thus, aspartate residues, Asp307/Asp389 and Asp273/Asp359, which are critical for the kinase activity of PIPKIα and PIPKIIα, respectively, are essential for
Fig 1. IRBIT interacts with PIPKα and PIPKIIα in mouse cerebellum. (A) Interaction between IRBIT and PIPK family members in heterologous cells. HA-IRBIT and myc-PIPK isoforms transfected into COS-7 cells were immunoprecipitated with anti-HA or anti-myc antibody. Immunoprecipitates were analyzed by Western blotting with anti-HA or anti-myc antibody. (B) Interaction between IRBIT and PIPK family members in mouse cerebellum.
interaction with IRBIT. These results suggest that IRBIT interacts with the catalytic core of PIPKIα and PIPKIβ, as with their phosphatidylinositol phosphate substrates.

To clarify further the possibility that IRBIT binds to the catalytic core of PIPKs, we tested whether the PIPK substrates, ATP, and Mg²⁺, which interact with the catalytic core of PIPKs, interfere with the interaction between IRBIT and PIPKIα/IIα. Pull-down assay using recombinant IRBIT showed that the binding of IRBIT to PIPKIα was suppressed by PI4P and 5 mM ATP, but not by PI5P, IP₃, ADP, and TTP (Fig 3A). On the other hand, the interaction between IRBIT and PIPKIΙβ was efficiently inhibited by 1–5 mM ATP, but not by PI4P, PI5P, IP₃, ADP, and TTP, in a dose-dependent manner (Fig 3B). As a control, IP₃ disrupted the interaction between IRBIT and the IP₃ binding domain (IP₃BD) of IP₃R (Fig 3C), as reported previously [2, 3]. A high concentration of Mg²⁺ (10 mM) reduced the binding of IRBIT to PIPKIα, but not to PIPKIΙβ, although physiological concentrations of Mg²⁺ (0.25–1 mM) [45] did not affect the interactions (Fig 3D). These results indicate that substances that bind to the catalytic core of PIPKs interfere with the IRBIT binding, supporting the hypothesis that IRBIT interacts with the catalytic core of PIPKIα and PIPKIβ. The mechanism of the interactions is different between PIPKIα and PIPKIΙβ, that is, the PIPKIα-IRBIT interaction is sensitive to PI4P, ATP, and Mg²⁺, whereas the PIPKIΙβ-IRBIT interaction is resistant to PI4P/PI5P and Mg²⁺, and is more sensitive to ATP than the PIPKIα-IRBIT interaction. Different affinities of the interactions and/or involvements of non-conserved amino acids in the catalytic core of PIPKIα and PIPKIΙβ might explain this difference. Intracellular ATP levels are approximately 1 mM in mammalian cells [46–48] and can be increased to several millimoles by extracellular stimuli [46, 49]. Thus, the interaction between IRBIT and PIPKs might be regulated by changes of cytosolic ATP concentrations.

Several lines of evidence suggest that IRBIT behaves as if its moiety mimics the structure or function of inositol phosphates or phosphoinositides. First, IRBIT binds to the IP₃-binding core of IP₃R by recognizing amino acids that interact with IP₃ [3, 50]. Second, IRBIT and PI (4,5)P₂ bind to the same domain of NBCe1-B and activate NBCe1-B, in part by a common mechanism [13]. Third, IRBIT binds to PIPKIα and PIPKIβ via amino acids that catalyze phosphatidylinositol phosphates (Fig 2D–2G), and PI4P inhibits the IRBIT-PIPKIβ interaction (Fig 3A). These findings suggest that phosphorylated serine/threonine residues of IRBIT (discussed below) simulate phosphate groups of inositol phosphates and phosphoinositides.

**Phosphorylation sites of IRBIT are essential for its interaction with PIPKIα and PIPKIβ**

IRBIT comprises an AHCY domain and an N-terminal extension containing a serine-rich region [2, 6] (Fig 4A). The serine-rich region (residues 62–103) is subject to multiple phosphorylations [3, 7, 8] that regulate IRBIT interactions with target proteins [3, 7, 9, 16, 17, 20, 21]. To clarify the involvement of the serine-rich region in the binding to PIPKs, we analyzed the interaction of IRBIT N-terminal deletion mutants with PIPKIα and PIPKIβ. IRBIT-(60–530) bound to both PIPKIα and PIPKIβ; however, IRBIT-(78–530) almost completely lost the ability to bind PIPKIα and PIPKIβ (Fig 4B and 4C), suggesting that critical binding determinants are located in the serine-rich region of IRBIT.
Several serine/threonine residues in the serine-rich region of IRBIT are phosphorylated. Ser68 is phosphorylated by protein kinase D [3, 7, 17]. Once Ser68 is phosphorylated, Ser71,
Fig 3. PI4P, ATP, or Mg$^{2+}$ interferes with the binding of IRBIT to PIPK$\alpha$ and PIPK$\alpha$.

(A, B, C) Recombinant IRBIT protein was processed for pull-down assay using GST-PIPK$\alpha$ (A), GST-PIPK$\alpha$ (B), or GST-IP$_3$BD (C) in the presence of the indicated concentrations of PI4P, PI5P, IP$_3$, ATP, ADP, or TTP. Bound proteins were analyzed by Western blotting with anti-IRBIT (top) and CBB staining (bottom). The relative binding of IRBIT to PIPK$\alpha$ and PIPK$\alpha$ are presented as mean ± SEM ($n = 3–4$). * $p < 0.05$, ** $p < 0.01$ (one-way ANOVA with post-hoc Tukey-Kramer test).

(D) IRBIT was pulled down with GST, GST-PIPK$\alpha$, or GST-PIPK$\alpha$ in the presence of 2 mM EDTA or 0.25, 1, 2.5, or 10 mM Mg$^{2+}$.

doi:10.1371/journal.pone.0141569.g003
Fig 4. Phosphorylation sites in the serine-rich region of IRBIT are essential for its interaction with PIPKα and PIPKIIα.

(A) The structure of IRBIT. The serine-rich region (red) and the AHCY domain (yellow) are indicated. (B-E) Interaction between deletion mutants (B, C) or site-directed mutants (D, E) of IRBIT and PIPKα (B, D) or PIPKIIα (C, E). HA-IRBIT mutants were transfected with myc-PIPKα or myc-PIPKIIα into COS-7 cells and were processed for immunoprecipitation with anti-HA or anti-myc antibody. Immunoprecipitates were analyzed by Western blotting with anti-HA or anti-myc antibody. (F) Quantification of (D) and (E). The relative binding of site-directed mutants of IRBIT to PIPKα and PIPKIIα are presented as mean +/- SEM (n = 4). * p < 0.05, ** p < 0.01, compared with wild-type (WT) IRBIT (one-way ANOVA with post-hoc Tukey’s HSD test). (G) Prediction of intrinsically disordered regions of IRBIT. Amino acid sequence of IRBIT was analyzed by three different meta-protein disorder prediction programs, metaDisorder [37], PONDR-FIT [38], and metaPrDOS [39]. Disordered regions predicted by three (red), two (orange), or one (yellow) programs are indicated.

doi:10.1371/journal.pone.0141569.g004
Ser74, and probably Ser77 are subsequently phosphorylated by casein kinase I [3, 7]. Thr82, Ser84, and Ser85 are phosphorylated in mouse brain [8]. Thus, we analyzed the interaction of site-directed mutants of serine/threonine residues in the IRBIT serine-rich region with PIPKIα and PIPKIIα. Mutation of Ser68 or Ser71 had the most prominent effect, showing almost complete loss of interaction with both PIPKIα and PIPKIIα (Fig 4D–4F). Mutation of Ser74, Thr82, or Ser84 markedly reduced the binding to PIPKIα, but had little effect on the binding to PIPKIIα. Mutation of Ser66, Ser70, or Ser80 also significantly decreased the interaction with PIPKIα, but not with PIPKIIα. In contrast, mutation of Ser77 profoundly decreased binding to PIPKIIα, but had less effect on the interaction with PIPKIα (Fig 4D–4F). Thus, Ser68 and Ser71 are commonly required for the interaction with PIPKIα and PIPKIIα, and Ser66/Ser70/Ser74/Ser80/Thr82/Ser84 and Ser77 are specifically important for the binding to PIPKIα and PIPKIIα, respectively. These results suggest that the phosphorylation status of the serine-rich region determines the binding specificity of IRBIT to PIPK isozymes. Furthermore, differences in the phosphorylation status of IRBIT between the cytosol and membrane fractions [2, 40] may explain the result that IRBIT bound to PIPKIIα in the membrane fraction but not in the cytosolic fraction (Fig 1B, S1 Fig).

The N-terminal region of IRBIT is intrinsically highly disordered

The serine-rich region of IRBIT is critically involved in its interaction with most of its binding partners [2, 3, 9, 10, 16, 17, 20–22]. The molecular mechanisms by which the serine-rich region interacts with diverse proteins that have no sequence or structural homology remain largely unknown. Circular dichroism spectroscopy and limited proteolysis analyses suggest that the N-terminal domain of IRBIT has a loose structure [51]. In addition, the crystal structure of IRBIT available in the Protein Data Bank (PDB number 3MTG) lacks the N-terminal 100 amino acids [52]. These observations suggest that the regions surrounding the serine-rich region have flexible structures. Thus, we investigated the structural order/disorder of IRBIT using meta-protein disorder prediction programs [37–39]. The in silico predictions revealed that the N-terminal approximately 100 amino acids of IRBIT containing the serine-rich region is highly disordered (Fig 4G), indicating that the N terminus of IRBIT belongs to the intrinsically disordered protein (IDP) regions [53].

The IDP regions do not form stable structures, and their instability is encoded by amino acid sequences [53]. The conformational flexibility of the IDP regions is beneficial for interactions with diverse proteins [54]. The structure and function of the IDP regions is regulated by phosphorylation [55, 56]. The structural flexibility of the serine-rich region of IRBIT may underlie the mechanism of its interactions with multiple divergent proteins and its regulation by phosphorylation, and may allow for its intrusions into the catalytic core of PIPKs (Fig 2D–2G) and the IP₃ binding core of IP₃R [3]. The IRBIT gene is assumed to emerge by gene duplication of an ancestral AHCY gene in the course of evolution [6]. The key roles of the serine-rich region in IRBIT function suggest that acquisition of the N-terminal IDP region confers IRBIT with crucial abilities to regulate diverse cellular processes required in higher organisms.

IRBIT does not regulate the kinase activity of PIPKIα and PIPKIIα

We tested whether IRBIT regulates the enzymatic activity of PIPKIα and PIPKIIα. In vitro production of PI(4,5)P₂ was measured using immunoprecipitates from COS-7 cells transfected with PIPKIα with or without IRBIT. IRBIT had no effect on the kinase activity of PIPKIα (Fig 5A). Similar results were obtained for PIPKIIα (Fig 5B). Further, we analyzed the activity of PIPKIα and PIPKIIα in MEF cells derived from IRBIT knockout mice [22]. Expression of PIPKIα and PIPKIIα did not differ between wild-type and IRBIT knockout MEF cells (Fig 5C).
vivo lipid kinase assays of immunoprecipitates with anti-PIPKIα or anti-PIPKIIα antibodies showed that IRBIT knockout did not influence PI(4,5)P2 production (Fig 5D and 5E). These results suggest that IRBIT does not regulate the lipid kinase activity of PIPKIα and PIPKIα.

The interaction of IRBIT with the catalytic core of PIPKIα and PIPKIα (Fig 2D–2G, Fig 3) may account for the inability of IRBIT to regulate the enzymatic activity of PIPKs. That is, the PI4P and/or ATP used in the in vitro lipid kinase assays might competitively disrupt the interaction between IRBIT and PIPKs. Therefore, we cannot exclude the possibility that IRBIT might regulate PIPK activity when the substrate concentration is extremely low.
IRBIT and PIPKs interact with NBCe1-B

We tested whether IRBIT and PIPKs form complexes with PI(4,5)P₂ effector proteins. IRBIT interacts with and activates the Na⁺/HCO₃⁻ cotransporter NBCe1-B [9–14], an ion transporter that mediates Na⁺-dependent HCO₃⁻ transport across the plasma membrane [37]. NBCe1-B activity is regulated by PI(4,5)P₂ [13, 35]. Thus, we examined the binding of PIPKIα to NBCe1-B by pull-down assay using the N-terminal cytoplasmic domain of NBCe1-B (NBCe1-B/N) [9]. Further, we tested the interaction of PIPKIα with IP₃R using the IP₃ binding domain (IP₃BD) of IP₃R [2], as IP₃, the agonist of IP₃R, is generated by the hydrolysis of PI (4,5)P₂. As shown in Fig 6A, PIPKIα interacted with NBCe1-B/N but not with IP₃BD, although IRBIT bound to both NBCe1-B/N and IP₃BD, as reported previously [2, 9]. These results suggest that IRBIT, PIPKIα, and NBCe1-B form a ternary complex. Further, we examined the interaction of PIPKIIα with NBCe1-B or IP₃R. IRBIT enhanced the interaction of PIPKIIα with NBCe1-B or IP₃R.
IRBIT interacts with phosphatidylinositol phosphate kinases

with NBCe1-B/N but not with IP₃BD (Fig 6B), suggesting that IRBIT recruits PIPKIα to NBCe1-B.

Next, we investigated intracellular localization of IRBIT, PIPKIα, PIPKIIα, and NBCe1-B in HeLa cells. When overexpressed alone, IRBIT and PIPKIIα were localized in the cytosol, whereas PIPKIα was localized at the plasma membrane (Fig 7A). Cells overexpressing PIPKIα showed a rounded cell shape due to actin re-organization induced by PI(4,5)P₂ production [29, 44] (Fig 7A). NBCe1-B was localized at the plasma membrane and intracellular vesicles (Fig 7A). When IRBIT was co-expressed with PIPKIα, or NBCe1-B, but not with PIPKIIα, IRBIT was partially localized near the plasma membrane (Fig 7B and 7C). IRBIT co-localized with NBCe1-B at the plasma membrane, but not on intracellular vesicles (Fig 7Bc). The effects of PIPKIα and NBCe1-B on the plasma membrane targeting of IRBIT might be additive (Fig 7B and 7C). IRBIT, PIPKIα, and NBCe1-B colocalized at the plasma membrane (Fig 7Bd). These results suggest that IRBIT, PIPKIα, and NBCe1-B form signaling complexes at the plasma membrane.

The physiological role of the complexes containing IRBIT, PIPKIα, and NBCe1-B is unclear. IRBIT directly activates NBCe1-B [9–14], whereas PIPKIα may indirectly potentiate the activity of NBCe1-B through the production of PI(4,5)P₂ in close proximity to NBCe1-B. IRBIT is most highly expressed in the brain [2, 40], and IRBIT knockout mice show behavioral abnormalities such as hyperactivity and increased social interactions [22]. PIPKIα is abundantly expressed in the brain and is responsible for the generation of specific PI4,5,P₂ pools [58]. In the brain, NBCe1-B plays a crucial role in the regulation of intracellular pH in neurons and astrocytes [59–62]. In fact, human patients with mutations in the NBCe1 gene (SLC4A4) show neurological abnormalities such as mental retardation and migraines [60, 63–66]. Thus, the signaling complex containing IRBIT, PIPKIα, and NBCe1-B may play an important role in the central nervous system. Compared to type I PIPKs, type II PIPKs play a minor role in PI(4,5)P₂ production, as the basal level of PI5P is only 0.5%–2% that of PI4P [67]. Therefore, the major function of type II PIPKs may be to control PI5P levels [68]. PI5P is the least characterized of the phosphoinositides; however, one of its functions is speculated to be the regulation of intracellular vesicle trafficking [68–70]. Thus, the IRBIT-PIPKIIα complex may regulate NBCe1-B trafficking. In the cerebellum, IRBIT bound to PIPKIα in the membrane fraction, but not in the cytosol (Fig 1B, S1 Fig); however, IRBIT colocalized with cytosolic PIPKIIα in HeLa cells (Fig 7Bb). This discrepancy may be explained by the abundant expression of NBCe1-B and its splicing variant, NBCe1-C, in brain [59, 60], and/or difference in phosphorylation status of IRBIT between brain and HeLa cells. Further studies are required to reveal physiological roles of the interaction between IRBIT, PIPKIα, NBCe1-B.

Conclusions

In this study, we demonstrated that IRBIT interacts with PIPKs, lipid kinases that generate PI(4,5)P₂. Specifically, IRBIT bound to PIPKIα and PIPKIIα isoforms in the cerebellum. Mutagenesis analysis and inhibition of the interaction by PI4P, Mg²⁺ and/or ATP suggest that IRBIT interacts with the catalytic core of PIPKIα and PIPKIIα through conserved catalytic aspartate residues. Phosphorylation sites in the serine-rich region of IRBIT are essential for the selectivity of its interaction with PIPKIα and PIPKIIα, suggesting the possibility that phosphorylated serine/threonine residues of IRBIT might simulate phosphate groups of phosphatidylinositol phosphate substrates. The structural flexibility of the N-terminal region of IRBIT may underlie the mechanism of its interactions with multiple divergent proteins. Furthermore, in vitro binding experiments and immunocytochemistry suggest that IRBIT and PIPKIα
**Fig 7.** IRBIT colocalizes with PIPKια and NBCe1-B at the plasma membrane in HeLa cells. (A) HA-IRBIT, myc-PIPKια, or myc-PIPKιλα were transfected into HeLa cells and immunostained with anti-HA or anti-myc antibody. GFP-NBCe1-B was transfected into HeLa cells and GFP fluorescence was observed. (B) HA-IRBIT was transfected into HeLa cells with myc-PIPKια (a), myc-PIPKιλα (b), GFP-NBCe1-B (c), myc-PIPKια and GFP-NBCe1-B (d), or myc-PIPKιλα and GFP-NBCe1-B (e). Cross-sectional plots of fluorescence intensities are shown below the images. Scale bars, 10 μm. (C) Plasma membrane/cytosol ratios of IRBIT fluorescence intensity. Mean +/- SEM are shown (28–33 cells from three independent experiments).

doi:10.1371/journal.pone.0141569.g007
interact with the Na"/HCO_3" cotransporter NBCe1-B. These results suggest that IRBIT forms signaling complexes with PIPKI\alpha and NBCe1-B, whose activity is regulated by PI(4,5)P_2.

Supporting Information

S1 Fig. IRBIT interacts with PIPKs in the presence of 1 mM Mg^{2+}. (A) Immunoprecipitation from heterologous cells using the lysis buffer containing 1 mM MgCl_2 and 1 mM EGTA instead of 2 mM EDTA. HA-IRBIT and myc-PIPK isoforms transfected into COS-7 cells were immunoprecipitated with anti-HA or anti-myc antibody. Immunoprecipitates were analyzed by Western blotting with anti-HA or anti-myc antibody. (B) Immunoprecipitation from mouse cerebellum using buffers containing 1 mM MgCl_2 and 1 mM EGTA instead of 2 mM EDTA. Cytosolic and membrane fractions were processed for immunoprecipitation with antibodies specific to each PIPK isoform or control (Ctrl) antibody, and immunoprecipitates were analyzed by Western blotting with antibodies indicated. Asterisks indicate immunoglobulin heavy chains.

(TIF)

Acknowledgments

We thank A. Mizutani and members of our labs for valuable discussions.

Author Contributions

Conceived and designed the experiments: HA KM. Performed the experiments: HA MH LG KK BB. Analyzed the data: HA. Contributed reagents/materials/analysis tools: T. Ijuin T. Itoh TT. Wrote the paper: HA.

References

1. Mikoshiba K. IP_3 receptor/Ca^{2+} channel: from discovery to new signaling concepts. J Neurochem. 2007; 102: 1426–1446. PMID:17697045
2. Ando H, Mizutani A, Matsu-ura T, Mikoshiba K. IRBIT, a novel inositol 1,4,5-trisphosphate (IP_3) receptor-binding protein, is released from the IP_3 receptor upon IP_3 binding to the receptor. J Biol Chem. 2003; 278: 10602–10612. PMID:12525476
3. Ando H, Mizutani A, Kiefer H, Tsuzurugi D, Michikawa T, Mikoshiba K. IRBIT suppresses IP_3 receptor activity by competing with IP_3 for the common binding site on the IP_3 receptor. Mol Cell. 2006; 22: 795–806. PMID:16793548
4. Devogelaere B, Nadif Kasri N, Derua R, Waelkens E, Callewaert G, Missiaen L, et al. Binding of IRBIT to the IP_3 receptor determinants and functional effects. Biochem Biophys Res Commun. 2006; 343: 49–56. PMID:16527252
5. Zaika O, Zhang J, Shapiro MS. Combined phosphoinositide and Ca^{2+} signals mediating receptor specificity toward neuronal Ca^{2+} channels. J Biol Chem. 2011; 286: 830–841. doi:10.1074/jbc.M110.166033 PMID:21051544
6. Ando H, Kawaai K, Mikoshiba K. IRBIT: A regulator of ion channels and ion transporters. Biochim Biophys Acta. 2014; 1843: 2185–2204. doi: 10.1016/j.bbamcr.2014.01.031 PMID:24518248
7. Devogelaere B, Beullens M, Sammels E, Derua R, Waelkens E, van Lint J, et al. Protein phosphatase-1 is a novel regulator of the interaction between IRBIT and the inositol 1,4,5-trisphosphate receptor. Biochem J. 2007; 407: 303–311. PMID:17893105
8. Collins MO, Yu L, Coba MP, Husi H, Campusano I, Blackstock WP, et al. Proteomic analysis of in vivo phosphorylated synaptic proteins. J Biol Chem. 2008; 283: 5972–5982.
9. Shirakabe K, Priori G, Yamada H, Ando H, Horita S, Fujita T, et al. IRBIT, an inositol 1,4,5-trisphosphate receptor-binding protein, specifically binds to and activates pancreas-type Na"/HCO_3" cotransporter 1 (pNBC1). Proc Natl Acad Sci U S A. 2006; 103: 9542–9547. PMID:16769980
10. Yang D, Shcheynikov N, Zeng W, Ohana E, So I, Ando H, et al. IRBIT coordinates epithelial fluid and HCO_3" secretion by stimulating the transporters pNBC1 and CFTR in the murine pancreatic duct. J Clin Invest. 2009; 119: 193–202. doi:10.1172/JCI36983 PMID:19033647
IRBIT Interacts with Phosphatidylinositol Phosphate Kinases

11. Lee SK, Boron WF, Parker MD. Relief of autoinhibition of the electrogenic Na/HCO₃ cotransporter NBCe1-B: role of IRBIT versus amino-terminal truncation. Am J Physiol Cell Physiol. 2012; 302: C518–C526. doi: 10.1152/ajpcell.00352.2011 PMID: 22012331

12. Yamaguchi S, Ishikawa T. IRBIT reduces the apparent affinity for intracellular Mg²⁺ in inhibition of the electrogenic Na⁺–HCO₃– cotransporter NBCe1-B. Biochim Biophys Res Commun. 2012; 424: 433–438. doi: 10.1016/j.bbrc.2012.06.127 PMID: 22771795

13. Hong JH, Yang D, Shcheynikov N, Ohana E, Shin DM, Muallem S. Convergence of IRBIT, phosphatidylinositol (4,5) bisphosphate, and WNK/SPAK kinases in regulation of the Na⁺–HCO₃– cotransporters family. Proc Natl Acad Sci U S A. 2013; 110: 4105–4110. doi: 10.1073/pnas.1221410110 PMID: 23431199

14. Shcheynikov N, Son A, Hong JH, Yamazaki O, Ohana E, Kurtz I, et al. Intracellular Cl⁻ as a signaling ion that potently regulates Na⁺/HCO₃– transporters. Proc Natl Acad Sci U S A. 2015; 112: E329–337. doi: 10.1073/pnas.1415673112 PMID: 25561556

15. He P, Zhang H, Yun CC IRBIT, inositol 1,4,5-trisphosphate (IP₃) receptor-binding protein released with IP₃, binds Na⁺/H⁺ exchanger NHE3 and activates NHE3 activity in response to calcium. J Biol Chem. 2008; 283: 33544–33553. doi: 10.1074/jbc.M805534200 PMID: 18829453

16. He P, Klein J, Yun CC. Activation of Na⁺/H⁺ exchanger NHE3 by angiotensin II is mediated by inositol 1,4,5-trisphosphate (IP₃) receptor-binding protein released with IP₃ (IRBIT) and Ca²⁺/calmodulin-dependent protein kinase II. J Biol Chem. 2010; 285: 27869–27878. doi: 10.1074/jbc.M110.133068 PMID: 20584908

17. He P, Zhao L, Zhu L, Weinman EJ, De Giorgio R, Koval M, et al. Restoration of Na⁺/H⁺ exchanger NHE3-containing macromolecular complexes ameliorates diabetes-associated fluid loss. J Clin Invest. 2015; 125: 3519–3531. doi: 10.1172/JCI79552 PMID: 26258413

18. Yang D, Li Q, So I, Huang CL, Ando H, Mizutani A, et al. IRBIT governs epithelial secretion in mice by antagonizing the WNK/SPAK kinase pathway. J Clin Invest. 2011; 121: 956–965. doi: 10.1172/JCI43475 PMID: 21317537

19. Park S, Shcheynikov N, Hong JH, Zheng C, Suh SH, Kawai K, et al. IRBIT mediates synergy between Ca²⁺ and cAMP signaling pathways during epithelial transport in mice. Gastroenterology. 2013; 145: 232–241. doi: 10.1053/j.gastro.2013.03.047 PMID: 23542070

20. Kiefer H, Mizutani A, Iemura S, Natsume T, Ando H, Kuroda Y, et al. Inositol 1,4,5-trisphosphate receptor-binding protein released with inositol 1,4,5-trisphosphate (IRBIT) associates with components of the mRNA 3’ processing machinery in a phosphorylation-dependent manner and inhibits polyadenylation. J Biol Chem. 2009; 284: 10694–10705. doi: 10.1074/jbc.M807136200 PMID: 19224921

21. Amaoutov A, Dasso M. IRBIT is a novel regulator of ribonucleotide reductase in higher eukaryotes. Science. 2014; 345: 1512–1515. doi: 10.1126/science.1251550 PMID: 25237103

22. Kawai K, Mizutani A, Shoji H, Ogawa N, Ebisui E, Kuroda Y, et al. IRBIT regulates CaMKIIα activity and contributes to catecholamine homeostasis through tyrosine hydroxylase phosphorylation. Proc Natl Acad Sci U S A. 2015; 112: 5515–5520. doi: 10.1073/pnas.1503310112 PMID: 25922519

23. Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature. 2006; 443: 651–657. PMID: 17035995

24. Sun Y, Thapa N, Hedman AC, Anderson RA. Phosphatidylinositol 4,5-bisphosphate: Targeted production and signaling. BioEssays. 2013; 35: 513–522. doi: 10.1002/bies.201200171 PMID: 23575577

25. Anderson RA, Boronenkov IV, Doughman SD, Kunz J, Loijens JC. Phosphatidylinositol phosphate kinases, a multifaceted family of signaling enzymes. J Biol Chem. 1999; 274: 9907–9910. PMID: 10187762

26. Heck JN, Mellman DL, Ling K, Sun Y, Wagoner MP, Schill NJ, et al. A conspicuous connection: structure defines function for the phosphatidylinositol-phosphate kinase family. Crit Rev Biochem Mol Biol. 2007; 42: 15–39. PMID: 17364683

27. Loijens JC, Anderson RA. Type I Phosphatidylinositol-4-phosphate 5-kinases are distinct members of this novel lipid kinase family. J Biol Chem. 1996; 271: 32937–32943. PMID: 8955136

28. Ishihara H, Shibasaki Y, Kizuki N, Katagiri H, Yazaki Y, Asano T, et al. Cloning of cDNAs encoding two isoforms of 68-kDa type I phosphatidylinositol 4-phosphate 5-kinase. J Biol Chem. 1996; 271: 23611–23614. PMID: 8798574

29. Ishihara H, Shibasaki Y, Kizuki N, Wada T, Yazaki Y, Asano T, et al. Type I phosphatidylinositol-4-phosphate 5-kinases. Cloning of the third isoform and deletion/substitution analysis of members of this novel lipid kinase family. J Biol Chem. 1998; 273: 8741–8748. PMID: 9535851

30. Boronenkov IV, Anderson RA. The sequence of phosphatidylinositol-4-phosphate 5-kinase defines a novel family of lipid kinases. J Biol Chem. 1995; 270: 2881–2884. PMID: 7852364
31. Castellino AM, Parker GJ, Boronenkov IV, Anderson RA, Chao MV. A novel interaction between the juxtamembrane region of the p55 tumor necrosis factor receptor and phosphatidylinositol-4-phosphate 5-kinase. J Biol Chem. 1997; 272: 5861–5870. PMID: 9038203

32. Itoh T, Ijuin T, Takenawa T. A novel phosphatidylinositol-5-phosphate 4-kinase (phosphatidylinositol-phosphate kinase Ily) is phosphorylated in the endoplasmic reticulum in response to mitogenic signals. J Biol Chem. 1998; 273: 20292–20299. PMID: 9685379

33. Rameh LE, Tolias KF, Duckworth BC, Cantley LC. A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate. Nature. 1997; 390: 192–196. PMID: 9367159

34. Choi S, Thapa N, Tan X, Hedman AC, Anderson RA. PIP kinases define PI4,5P2 signaling specificity by association with effectors. Biochim Biophys Acta. 2015; 1851: 711–723. doi: 10.1016/j.bbalip.2015.01.009 PMID: 25617736

35. Thornell IM, Bevensee MO. Phosphatidylinositol 4,5-bisphosphate degradation inhibits the Na+/bicarbonate cotransporter NBCe1-B and -C variants expressed in Xenopus oocytes. J Physiol. 2015; 593: 541–558. doi: 10.1113/jphysiol.2014.284307 PMID: 25398525

36. Park SJ, Itoh T, Takenawa T. Phosphatidylinositol 4-phosphate 5-kinase type I is regulated through phosphorylation response by extracellular stimuli. J Biol Chem. 2001; 276: 4781–4787. PMID: 11087761

37. Kozłowski LP, Bujnicki JM. MetaDisorder: a meta-server for the prediction of intrinsic disorder in proteins. BMC Bioinformatics. 2012; 13: 111. doi: 10.1186/1471-2105-13-111 PMID: 22624656

38. Xue B, Dunbrack RL, Williams RW, Dunker AK, Uversky VN. PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. Biochim Biophys Acta. 2010; 1801: 997–1008. doi: 10.1016/j.bbapap.2010.01.011 PMID: 20100603

39. Ishida T, Kinoshita K. Prediction of disordered regions in proteins based on the meta approach. Bioinformatics. 2008; 24: 1344–1348. doi: 10.1093/bioinformatics/btn195 PMID: 18426805

40. Ando H, Mizutani A, Mikoshiba K. An IRBIT homologue lacks binding activity to inositol 1,4,5-trisphosphate receptor due to the unique N-terminal appendage. J Neurochem. 2009; 109: 539–550. doi: 10.1111/j.1471-4159.2009.05979.x PMID: 19220705

41. Rao VD, Misra S, Boronenkov IV, Anderson RA, Hurley JH. Structure of type II IRBIT Interacts with Phosphatidylinositol Phosphate Kinases: a protein kinase fold flattened for interfacial phosphorylation. Cell. 1998; 94: 829–839. PMID: 9753329

42. Fairn GD, Ogata K, Botelho RJ, Stahl PD, Anderson RA, De Camilli P, et al. An electrostatic switch displaces phosphatidylinositol phosphate kinases from the membrane during phagocytosis. J Cell Biol. 2009; 187: 701–714. doi: 10.1083/jcb.200909025 PMID: 19951917

43. Coppolino MG, Dierckman R, Loijens J, Collins RF, Pouladi M, Jongstra-Bilen J, et al. Inhibition of phosphatidylinositol-4-phosphate 5-kinase type I impairs localized actin remodeling and suppresses phagocytosis. J Biol Chem. 2002; 277: 43849–43857. PMID: 12223494

44. Shibasaki Y, Ishihara H, Kizuki N, Asano T, Oka Y, Yazaki Y. Massive actin polymerization induced by phosphatidylinositol-4-phosphate 5-kinase in vivo. J Biol Chem. 1997; 272: 7578–7581. PMID: 9065410

45. Grubbs RD. Intracellular magnesium and magnesium buffering. Biometals. 2002; 15: 251–259. PMID: 12206391

46. Kennedy HJ, Pouli AE, Ainscow EK, Jouaville LS, Rutter GA. Glucose generates submembrane ATP microdomains in single islet β-cells. Potential role for strategically located mitochondria. J Biol Chem. 1999; 274: 13281–13291. PMID: 10224088

47. Gribble FM, Loussouarn G, Tucker SJ, Zhao C, Nichols CG, Ashcroft FM. A novel method for measurement of submembrane ATP concentration. J Biol Chem. 2000; 275: 30046–30049. PMID: 10866996

48. Wang RH, Tao L, Trumbore MW, Berger SL. Turnover of the acyl phosphates of human and murine prothymosin α in vivo. J Biol Chem. 1997; 272: 26405–26412. PMID: 9334215

49. Zamaraeva MV, Sabirov RZ, Maeno E, Ando-Akatsuka Y, Bessonova SV, Okada Y. Cells die with increased cytosolic ATP during apoptosis: a bioluminescence study with intracellular luciferase. Cell Death Differ. 2005; 12: 1390–1397. PMID: 15905877

50. Bosanac I, Alattia JR, Mal TK, Chan J, Talarico S, Tong FK, et al. Structure of the inositol 1,4,5-trisphosphate receptor binding core in complex with its ligand. Nature. 2002; 420: 696–700. PMID: 12442173

51. Gomi T, Takusagawa F, Nishizawa M, Agussalim B, Usul I, Sugiyama E, et al. Cloning, bacterial expression, and unique structure of adenosylhomocysteine hydrolase-like protein 1, or inositol 1,4,5-trisphosphate receptor-binding protein from mouse kidney. Biochim Biophys Acta. 2008; 1784: 1786–1794. doi: 10.1016/j.bbapap.2008.08.016 PMID: 18804558
52. Wisniewska M, Siponen MI, Arrowsmith CH, Berglund H, Bountra C, Collins R, et al. Crystal structure of human S-adenosyl homocysteine hydrolase-like 1 protein. 2010. Database: Protein Data Bank [Internet]. Available: http://www.rcsb.org/pdb/explore/explore.do?structureId=3MTG.

53. Oldfield CJ, Dunker AK. Intrinsically Disordered Proteins and Intrinsically Disordered Protein Regions. Annu Rev Biochem. 2014; 83: 553–584. doi: 10.1146/annurev-biochem-072711-164947 PMID: 24606139

54. Dunker AK, Cortese MS, Romero P, lakoucheva LM, Uversky VN. Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBJ. 2005; 272: 5129–5148. PMID: 16218947

55. Pufall MA, Lee GM, Nelson ML, Kang HS, Velyvis A, Kay LE, et al. Variable control of Ets-1 DNA binding by multiple phosphates in an unstructured region. Science. 2005; 309: 142–145. PMID: 15994560

56. Bah A, Vernon RM, Siddiqui Z, Krzeminski M, Muhandiram R, Zhao C, et al. Folding of an intrinsically disordered protein by phosphorylation as a regulatory switch. Nature. 2015; 519: 106–109. doi: 10.1038/nature13999 PMID: 25533957

57. Romero MF, Chen AP, Parker MD, Boron WF. The SLC4 family of bicarbonate (HCO3−) transporters. Mol Aspects Med. 2013; 34: 159–182. doi: 10.1016/j.mam.2012.10.008 PMID: 23506864

58. Volpicelli-Daley LA, Lucast L, Gong LW, Liu L, Sasaki J, Sasaki T, et al. Phosphatidylinositol-4-phosphate 5-kinases and phosphatidylinositol 4,5-bisphosphate synthase in the brain. J Biol Chem. 2010; 285: 28708–28714. doi: 10.1074/jbc.M110.132191 PMID: 20622009

59. Majumdar D, Maunsbach AB, Shacka JJ, Williams JB, Berger UV, Schultz KP, et al. Localization of electrionic Na bicarbonate cotransporter NBCe1 variants in rat brain. Neuroscience. 2008; 155: 818–832. doi: 10.1016/j.neuroscience.2008.05.037 PMID: 18582537

60. Majumdar D, Bевensee MO. Na-coupled bicarbonate transporters of the solute carrier 4 family in the nervous system: function, localization, and relevance to neurologic function. Neuroscience. 2010; 171: 951–972. doi: 10.1016/j.neuroscience.2010.09.037 PMID: 20884330

61. Svichar N, Esquenazi S, Chen HY, Chesler M. Preemptive regulation of intracellular pH in hippocampal neurons by a dual mechanism of depolarization-induced alkalization. J Neurosci. 2011; 31: 6997–7004. doi: 10.1523/JNEUROSCI.0608-10.2011 PMID: 21562261

62. Theparambil SM, Ruminot I, Schneider HP, Shull GE, Deitmer JW. The electrogenic sodium bicarbonate cotransporter NBCe1 is a high-affinity bicarbonate carrier in cortical astrocytes. J Neurosci. 2014; 34: 1148–1157. doi: 10.1523/JNEUROSCI.2377-13.2014 PMID: 24453308

63. Igarashi T, Inatomi J, Sekine T, Cha SH, Kanai Y, Kunimi M, et al. Mutations in SLC4A4 cause permanent isolated proximal renal tubular acidosis with ocular abnormalities. Nat Genet. 1999; 23: 264–266. PMID: 10549389

64. Horita S, Yamada H, Inatomi J, Moriyama N, Sekine T, Igarashi T, et al. Functional analysis of NBC1 mutants associated with proximal renal tubular acidosis and ocular abnormalities. J Am Soc Nephrol. 2005; 16: 2270–2278. PMID: 15930088

65. Demirci FY, Chang MH, Mah TS, Romero MF, Gorin MB. Proximal renal tubular acidosis and ocular pathology: a novel missense mutation in the gene (SLC4A4) for sodium bicarbonate cotransporter protein (NBCe1). Mol Vis. 2006; 12: 324–330. PMID: 16636648

66. Suzuki M, Van Paesschen W, Stalmans I, Horita S, Yamada H, Bergmans BA, et al. Defective membrane expression of the Na+-HCO3− cotransporter NBCe1 is associated with familial migraine. Proc Natl Acad Sci U S A. 2010; 107: 15963–15968. doi: 10.1073/pnas.100780107 PMID: 20798035

67. Sarkes D, Rameh LE. A novel HPLC-based approach makes possible the spatial characterization of cellular PtdIns5P and other phosphoinositides. Biochem J. 2010; 428: 375–384. doi: 10.1042/BJ20100129 PMID: 20370717

68. Bulley SJ, Clarke JH, Droubi A, Giudici ML, Irvine RF. Exploring phosphatidylinositol 5-phosphate 4-kinase function. Adv Biol Regul. 2015; 57: 193–202. doi: 10.1016/j.bior.2014.09.007 PMID: 25311266

69. Lecompte O, Poch O, Laporte J. PtdIns5P regulation through evolution: roles in membrane trafficking? Trends Biochem Sci. 2008; 33: 453–460. doi: 10.1016/j.tibs.2008.07.002 PMID: 18774718

70. Grainger DL, Tavelis C, Ryan AJ, Hinchliffe KA. The emerging role of PtdIns5P: another signalling phosphoinositide takes its place. Biochem Soc Trans. 2012; 40: 257–261. doi: 10.1042/BST20110617 PMID: 22260701